Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC) will be presented at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium in Orlando, Florida. Dr. Martin H. Voss, medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the DART clinical trial, will present the data in an oral session on February 28, 2015. The DART study data will also be presented as a poster presentation during the meeting.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
